Head-to-Head Comparison between Peptide-Based Radiopharmaceutical for PET and SPECT in the Evaluation of Neuroendocrine Tumors: A Systematic Review.
111In-DTPA(0)-octreotide
68Ga-DOTA(0)-Phe(1)-Tyr(3)-octreotide
68Ga-DOTANOC
99mTc-EDDA/HYNIC-TOC
PET
SPECT
gallium Ga 68 DOTATATE
Journal
Current issues in molecular biology
ISSN: 1467-3045
Titre abrégé: Curr Issues Mol Biol
Pays: Switzerland
ID NLM: 100931761
Informations de publication
Date de publication:
07 Nov 2022
07 Nov 2022
Historique:
received:
04
08
2022
revised:
03
11
2022
accepted:
04
11
2022
entrez:
10
11
2022
pubmed:
11
11
2022
medline:
11
11
2022
Statut:
epublish
Résumé
We compared head-to-head the most used radiolabeled peptides for single photon computed emission tomography (SPECT) and positron emission tomography (PET) imaging of neuroendocrine tumors (NETs). A comprehensive literature search was performed in PubMed, Web of Science, and Scopus databases. The following words, coupled two by two, were used:
Identifiants
pubmed: 36354685
pii: cimb44110373
doi: 10.3390/cimb44110373
pmc: PMC9689511
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
5516-5530Références
J Nucl Med. 2010 Jun;51(6):875-82
pubmed: 20484441
Horm Metab Res. 2010 Jul;42(8):599-606
pubmed: 20422506
EJNMMI Res. 2021 Feb 25;11(1):20
pubmed: 33630166
J Nucl Med. 2015 Jun;56(6):847-54
pubmed: 25952736
J Nucl Med. 2020 Dec;61(12):1800-1805
pubmed: 32414949
Mol Imaging Biol. 2011 Jun;13(3):583-593
pubmed: 20652423
J Nucl Med. 2020 Jun;61(6):897-903
pubmed: 31676731
Scand J Gastroenterol. 2015 Jun;50(6):740-7
pubmed: 25959100
Future Oncol. 2014 Nov;10(14):2259-77
pubmed: 25471038
J Nucl Med. 2003 May;44(5):708-16
pubmed: 12732671
Clin Endocrinol (Oxf). 2021 Oct;95(4):595-605
pubmed: 34018606
Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1617-26
pubmed: 17520251
J Nucl Med. 2007 Apr;48(4):508-18
pubmed: 17401086
Hell J Nucl Med. 2020 May-Aug;23(2):188-200
pubmed: 32716410
J Nucl Med. 2020 Jul;61(7):1014-1020
pubmed: 31806775
Clin Nucl Med. 2015 May;40(5):e271-7
pubmed: 25642915
J Nucl Med. 2019 Sep;60(9):1266-1269
pubmed: 30850506
Mol Imaging Biol. 2003 Jan-Feb;5(1):42-8
pubmed: 14499161
Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):72-82
pubmed: 21927931
J Am Coll Surg. 2015 Aug;221(2):509-17
pubmed: 26206648
J Med Imaging Radiat Oncol. 2012 Feb;56(1):40-7
pubmed: 22339744
Biochim Biophys Acta Mol Basis Dis. 2020 Jun 1;1866(6):165717
pubmed: 32035103
J Nucl Med. 2018 Jun;59(6):915-921
pubmed: 29191855
J Labelled Comp Radiopharm. 2019 Aug;62(10):635-645
pubmed: 31112618
Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16
pubmed: 23389427
Cancer. 2005 Oct 15;104(8):1590-602
pubmed: 16134179
Endocr Relat Cancer. 2005 Dec;12(4):1083-92
pubmed: 16322345
J Nucl Med. 2013 Mar;54(3):364-72
pubmed: 23297077
Nucl Med Rev Cent East Eur. 2016;19(2):88-92
pubmed: 27479886
Clin Nucl Med. 2017 Dec;42(12):905-911
pubmed: 29076910
Eur Radiol. 2016 Mar;26(3):900-9
pubmed: 26162577
Eur J Nucl Med. 2000 Jun;27(6):628-37
pubmed: 10901448
Radiol Imaging Cancer. 2022 May;4(3):e210095
pubmed: 35621524
J Nucl Med. 2022 Sep;63(9):1300-1301
pubmed: 35618479
J Nucl Med. 2019 Jun;60(6):777-785
pubmed: 30442752
J Nucl Med. 2017 Mar;58(3):451-457
pubmed: 27660147
Curr Treat Options Oncol. 2019 Aug 29;20(10):78
pubmed: 31468190
Endocrine. 2012 Aug;42(1):80-7
pubmed: 22350660
Eur J Nucl Med. 2001 Dec;28(12):1751-7
pubmed: 11734911
Eur J Nucl Med. 2000 Sep;27(9):1318-25
pubmed: 11007513
Curr Oncol Rep. 2017 Feb;19(2):9
pubmed: 28220446
PET Clin. 2014 Jan;9(1):71-82
pubmed: 25029936